Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 384

The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.

Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus–Unrelated Head and Neck Cancer: A Multicenter, Phase II Trial

Open access
Uppaluri, Ravindra, Campbell, Katie M., Egloff, Ann Marie, Zolkind, Paul, Skidmore, Zachary L., Nussenbaum, Brian, Paniello, Randal C., Rich, Jason T., Jackson, Ryan, Pipkorn, Patrik, Michel, Loren S., Ley, Jessica, Oppelt, Peter, Dunn, Gavin P., Barnell, Erica K., Spies, Nicholas C., Lin, Tianxiang, Li, Tiantian, Mulder, David T., Hanna, Youstina, Cirlan, Iulia, Pugh, Trevor J., Mudianto, Tenny, Riley, Rachel, Zhou, Liye, Jo, Vickie Y., Stachler, Matthew D., Hanna, Glenn J., Kass, Jason, Haddad, Robert, Schoenfeld, Jonathan D., Gjini, Evisa, Lako, Ana, Thorstad, Wade, Gay, Hiram A., Daly, Mackenzie, Rodig, Scott J., Hagemann, Ian S., Kallogjeri, Dorina, Piccirillo, Jay F., Chernock, Rebecca D., Griffith, Malachi, Griffith, Obi L., Adkins, Douglas R.·2020·Clinical Cancer Research

Abstract

Purpose: Pembrolizumab improved survival in patients with recurrent or metastatic head and neck squamous-cell carcinoma (HNSCC). The aims of this study were to determine if pembrolizumab would be safe, result in pathologic tumor response (pTR), and lower the relapse rate in patients with resectable human papillomavirus (HPV)–unrelated HNSCC. Patients and Methods: Neoadjuvant pembrolizumab (200 mg) was administered and followed 2 to 3 weeks later by surgical tumor ablation. Postoperative (chemo)radiation was planned. Patients with high-risk pathology (positive margins and/or extranodal extension) received adjuvant pembrolizumab. pTR was quantified as the proportion of the resection bed with tumor necrosis, keratinous debris, and giant cells/histiocytes: pTR-0 (<10%), pTR-1 (10%–49%), and pTR-2 (≥50%). Coprimary endpoints were pTR-2 among all patients and 1-year relapse rate in patients with high-risk pathology (historical: 35%). Correlations of baseline PD-L1 and T-cell infiltration with pTR were assessed. Tumor clonal dynamics were evaluated (ClinicalTrials.gov NCT02296684). Results: Thirty-six patients enrolled. After neoadjuvant pembrolizumab, serious (grades 3–4) adverse events and unexpected surgical delays/complications did not occur. pTR-2 occurred in eight patients (22%), and pTR-1 in eight other patients (22%). One-year relapse rate among 18 patients with high-risk pathology was 16.7% (95% confidence interval, 3.6%–41.4%). pTR ≥10% correlated with baseline tumor PD-L1, immune infiltrate, and IFNγ activity. Matched samples showed upregulation of inhibitory checkpoints in patients with pTR-0 and confirmed clonal loss in some patients. Conclusions: Among patients with locally advanced, HPV-unrelated HNSCC, pembrolizumab was safe, and any pathologic response was observed in 44% of patients with 0% pathologic complete responses. The 1-year relapse rate in patients with high-risk pathology was lower than historical.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-20-1695

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 37 references

Cited by

See all 384

Metadata

Authors
Uppaluri, R., Campbell, K. M., Egloff, A. M., Zolkind, P., Skidmore, Z. L., Nussenbaum, B., Paniello, R. C., Rich, J. T., Jackson, R., Pipkorn, P., Michel, L. S., Ley, J., Oppelt, P., Dunn, G. P., Barnell, E. K., Spies, N. C., Lin, T., Li, T., Mulder, D. T., Hanna, Y., Cirlan, I., Pugh, T. J., Mudianto, T., Riley, R., Zhou, L., Jo, V. Y., Stachler, M. D., Hanna, G. J., Kass, J., Haddad, R., Schoenfeld, J. D., Gjini, E., Lako, A., Thorstad, W., Gay, H. A., Daly, M., Rodig, S. J., Hagemann, I. S., Kallogjeri, D., Piccirillo, J. F., Chernock, R. D., Griffith, M., Griffith, O. L., & Adkins, D. R.
Venue
Clinical Cancer Research
Published
2020-10-01
Volume
26
Issue
19
Pages
5140-5152
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W3042708039
Cited by
384
References
37
FWCI
32.50
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus–Unrelated Head and Neck Cancer: A Multicenter, Phase II Trial. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-20-1695
The paper
Uppaluri, R., Campbell, K. M., Egloff, A. M., Zolkind, P., Skidmore, Z. L., Nussenbaum, B., Paniello, R. C., Rich, J. T., Jackson, R., Pipkorn, P., Michel, L. S., Ley, J., Oppelt, P., Dunn, G. P., Barnell, E. K., Spies, N. C., Lin, T., Li, T., Mulder, D. T., . . . Adkins, D. R. (2020). Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus–Unrelated Head and Neck Cancer: A Multicenter, Phase II Trial. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-20-1695

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.